Olema Pharmaceuticals, Inc.
(NASDAQ : OLMA)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 1.07%171.790.7%$1114.12m
AZNAstraZeneca Plc 0.47%58.231.0%$926.89m
PFEPfizer Inc. 0.60%41.720.9%$889.74m
MRKMerck & Co., Inc. 1.36%77.570.7%$779.19m
LLYEli Lilly & Co. 2.47%244.381.1%$746.72m
ABBVAbbVie, Inc. 0.50%118.131.9%$709.77m
BMYBristol-Myers Squibb Co. 0.50%68.301.0%$595.22m
NRXPNRX Pharmaceuticals, Inc. 50.58%24.770.0%$217.95m
GSKGlaxoSmithKline Plc 0.74%39.520.2%$168.81m
CERECerevel Therapeutics Holdings, Inc. -1.28%24.670.2%$150.46m
NVSNovartis AG 0.57%91.600.2%$149.70m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. 2.88%126.460.0%$93.07m
VTRSViatris, Inc. 0.51%13.920.0%$86.53m
OGNOrganon & Co. -3.66%29.790.0%$80.48m
ANVSAnnovis Bio, Inc. 12.03%120.000.0%$76.82m

Company Profile

Olema Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of targeted therapies for women's cancers. The company also focuses on OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD) that is being studied in a Phase 1/2 clinical trial for the treatment of metastatic or locally advanced ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema Pharmaceuticals was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.